Seattle Genetics Initiates Phase 1 LIV-1-Positive Metastatic Breast Cancer Trial of SGN-LIV1A
October 21, 2013 at 09:17 AM EDT
Seattle Genetics (NASDAQ: SGEN ) today announced the initiation of a phase 1 clinical trial evaluating SGN-LIV1A for patients with LIV-1-positive metastatic breast cancer. SGN-LIV1A utilizes Seattle
